Mycophenolate Mofetil Ameliorates Diabetic Nephropathy in db/db Mice

Area of Science:

• Nephrology
• Immunology
• Endocrinology

Background:

• Diabetic nephropathy is a severe complication driven by chronic low-grade inflammation.
• Mycophenolate mofetil (MMF) is known for its anti-inflammatory properties and ability to inhibit lymphocyte proliferation.
• Previous research suggested MMF could attenuate diabetic nephropathy, but mechanisms remained unclear.

Purpose of the Study:

• To investigate the therapeutic effects of MMF on diabetic nephropathy in a type 2 diabetes mouse model.
• To elucidate the underlying mechanisms by which MMF exerts its protective effects against diabetic kidney disease.

Main Methods:

• Type 2 diabetic db/db mice and control db/m mice were treated with MMF (30 mg/kg/day) or vehicle for 12 weeks.
• Evaluated parameters included albuminuria, kidney histology (mesangial expansion), gene expression (profibrotic markers, chemokines), immune cell infiltration (CD4+, CD8+ T cells, macrophages), and expression of podocyte markers (nephrin, WT1).

Main Results:

• MMF treatment significantly reduced albuminuria, mesangial expansion, and profibrotic gene expression in diabetic mice.
• MMF decreased the infiltration of CD4+ and CD8+ T cells and macrophages in the kidneys, lowering intrarenal TNF-α and IL-17 levels.
• MMF treatment restored the expression of glomerular nephrin and WT1, crucial for kidney function, independent of glycemic control.

Conclusions:

• Mycophenolate mofetil effectively prevents the progression of diabetic nephropathy in a mouse model.
• MMF's renoprotective effects are primarily mediated through the regulation of T cell responses and associated inflammatory cytokines.
• MMF represents a potential therapeutic strategy for diabetic nephropathy, acting independently of blood glucose levels.